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1. INTRODUCTION {#all13209-sec-0005}
===============

Chronic spontaneous urticaria (CSU) (also called chronic idiopathic urticaria)[1](#all13209-bib-0001){ref-type="ref"} is characterized by the occurrence of urticaria for 6 weeks or longer without identifiable specific triggers.[2](#all13209-bib-0002){ref-type="ref"} The average duration of CSU is frequently reported as 5 years[3](#all13209-bib-0003){ref-type="ref"}, [4](#all13209-bib-0004){ref-type="ref"}, [5](#all13209-bib-0005){ref-type="ref"} but may be longer in more severe cases[3](#all13209-bib-0003){ref-type="ref"}, [4](#all13209-bib-0004){ref-type="ref"}---specifically, in patients with concurrent angioedema,[4](#all13209-bib-0004){ref-type="ref"}, [6](#all13209-bib-0006){ref-type="ref"}, [7](#all13209-bib-0007){ref-type="ref"} CSU in combination with inducible urticaria,[4](#all13209-bib-0004){ref-type="ref"}, [7](#all13209-bib-0007){ref-type="ref"} or a positive autologous serum skin test.[1](#all13209-bib-0001){ref-type="ref"}, [8](#all13209-bib-0008){ref-type="ref"} The estimated point prevalence of CSU is approximately 0.5% to 1%.[9](#all13209-bib-0009){ref-type="ref"} Until omalizumab was approved in early 2014, H~1~‐antihistamines were the only approved medication for CSU and were the mainstay of symptomatic treatment. However, over 60% of patients remain symptomatic despite treatment with second‐generation H~1~‐antihistamines at the licensed dose.[10](#all13209-bib-0010){ref-type="ref"}

Available evidence indicates that all forms of chronic urticaria can substantially affect patients' quality of life (QoL), ability to perform daily tasks, and mental health.[11](#all13209-bib-0011){ref-type="ref"}, [12](#all13209-bib-0012){ref-type="ref"}, [13](#all13209-bib-0013){ref-type="ref"}, [14](#all13209-bib-0014){ref-type="ref"} Patients with chronic urticaria (used as a proxy for CSU) experience substantial health‐related quality of life (HRQoL) and productivity impairments and increased psychological comorbidities relative to patients without chronic urticaria.[15](#all13209-bib-0015){ref-type="ref"}, [16](#all13209-bib-0016){ref-type="ref"}, [17](#all13209-bib-0017){ref-type="ref"} Nevertheless, real‐world research quantifying the humanistic and economic impact of diagnosed CSU is limited, and a number of unmet needs exist in this patient population,[9](#all13209-bib-0009){ref-type="ref"} particularly among those refractory to standard treatment.

The ASSURE‐CSU (ASSessment of the Economic and Humanistic Burden of Chronic Spontaneous/Idiopathic URticaria patiEnts) study sought to improve understanding of CSU and to explore the unmet needs of patients whose disease has persisted for longer than 12 months and is inadequately controlled by standard treatment. Specifically, the main objectives of this study were to characterize, in this population, disease duration, disease activity, and treatment history, as well as to identify and quantify the humanistic, societal, and economic burden of CSU.

2. METHODS {#all13209-sec-0006}
==========

2.1. Study design and participants {#all13209-sec-0007}
----------------------------------

The study design has previously been described in detail.[18](#all13209-bib-0018){ref-type="ref"} Briefly, this noninterventional, multinational, and multicenter study was conducted in Canada, France, Germany, Italy, Spain, the Netherlands, and the United Kingdom (UK). Recruitment of 700 patients was planned. Data collection occurred from October 2013 until May 2015, with each center recruiting over a 4‐month period. Figure [S1](#all13209-sup-0001){ref-type="supplementary-material"} describes the patient selection process. Eligible patients were adults with a clinician‐confirmed diagnosis of CSU[19](#all13209-bib-0019){ref-type="ref"} who had received at least one treatment course with an H1‐antihistamine and were symptomatic despite treatment.[18](#all13209-bib-0018){ref-type="ref"}

The study was reviewed and exempted by the RTI International Institutional Review Board and was reviewed and approved by the relevant national, local, and site‐level ethics committees. The study was conducted in accordance with the Declaration of Helsinki;[20](#all13209-bib-0020){ref-type="ref"} all patients provided written informed consent.

2.2. Study measures {#all13209-sec-0008}
-------------------

The study included a 12‐month retrospective medical record abstraction, a cross‐sectional patient survey administered at enrollment, and a patient diary completed over an 8‐day period after recruitment (Figure [1](#all13209-fig-0001){ref-type="fig"}). Both the survey[21](#all13209-bib-0021){ref-type="ref"}, [22](#all13209-bib-0022){ref-type="ref"}, [23](#all13209-bib-0023){ref-type="ref"}, [24](#all13209-bib-0024){ref-type="ref"}, [25](#all13209-bib-0025){ref-type="ref"} and the patient diary[26](#all13209-bib-0026){ref-type="ref"}, [27](#all13209-bib-0027){ref-type="ref"}, [28](#all13209-bib-0028){ref-type="ref"} included study‐specific questions and validated PRO measures‎ (Table [S1](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S1).

![Study measures. AE‐QoL=Angioedema Quality of Life Questionnaire; CU‐Q~2~oL=Chronic Urticaria Quality of Life Questionnaire; d=days; DLQI=Dermatology Life Quality Index; UAS7=Urticaria Activity Score over 7 days, twice‐daily assessment; UPDD=Urticaria Patient Daily Diary; WPAI‐SHP=Work Productivity and Activity Impairment‐Specific Health Problem](ALL-72-2005-g001){#all13209-fig-0001}

Direct and indirect costs were estimated for each country. Direct costs included CSU‐related treatments, physician visits, emergency department (ED) visits, and hospitalizations documented in medical records, as well as CSU‐related alternative medicine, other out‐of‐pocket costs, and transportation reported in the patient survey. Indirect costs included the cost of patient‐reported workdays missed and lost productivity due to CSU.

2.3. Data analysis {#all13209-sec-0009}
------------------

Data analyses were descriptive. Data from all countries were pooled for all outcomes except for direct and indirect costs. With the exception of imputation of missing start dates for therapy data, no imputation of missing data was performed, and no formal hypothesis testing was conducted. Descriptive tables were generated overall and stratified by Urticaria Activity Score over 7 days, twice‐daily assessment (UAS7) score bands. These score bands categorize the UAS7 into four levels of disease activity: UAS7=0‐6 (urticaria‐free or well‐controlled urticaria activity), 7‐15 (mild activity), 16‐27 (moderate activity), and 28‐42 (severe activity).[29](#all13209-bib-0029){ref-type="ref"}, [30](#all13209-bib-0030){ref-type="ref"} Mean values, standard deviations (SDs), medians, and ranges were computed for continuous variables; counts were collected and percentages were computed for categorical variables. All analyses were performed using SAS version 9.3 or later (Cary, North Carolina, USA: SAS Institute, Inc.; 2011).

For the direct cost calculations, costing algorithms were used to assign 2014 unit costs from published sources in the respective country\'s currency to the resource utilization data.[31](#all13209-bib-0031){ref-type="ref"} Indirect costs for workdays missed and lost productivity due to CSU were calculated by the human capital approach using each country\'s specific average wage and hours worked.[32](#all13209-bib-0032){ref-type="ref"} Pooled cost calculations were not conducted. Country costs were converted to purchasing power parity dollars (PPP\$) using published methodology and sources.[33](#all13209-bib-0033){ref-type="ref"} All cost calculations were performed using Microsoft Excel 2010.

3. RESULTS {#all13209-sec-0010}
==========

3.1. Patient population {#all13209-sec-0011}
-----------------------

A total of 673 patients were enrolled in 64 recruiting centers, primarily hospital‐based specialist centers (Table [S2](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S2). Most enrolled patients were female (72.7%) and Caucasian/white (90.4%), with a mean (SD) age of 48.8 (15.47) years (Table[1](#all13209-tbl-0001){ref-type="table-wrap"}). The mean (SD) duration of disease from symptom onset to diagnosis was 24.0 (63.36) months (median 4.7 months) and from diagnosis to the time of study enrollment was 57.7 (77.79) months (median 27.7 months). At diagnosis, 11.2% of patients were assessed by their physician as having mild CSU, 31.4% as moderate, and 36.5% as severe; severity at diagnosis was not available for 21.0% of patients (Table [S3](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S3). Most physicians reported using a combination of factors to assess CSU severity, including number, duration, and intensity of flares (58.5%) and impact on QoL (38.0%); some reported using validated PRO measures, including the UAS7 (15.9%). Allergic rhinitis (16.5%), personal history or family history of allergic disease (14.0% and 14.1%, respectively), and asthma (11.3%) were the most frequently reported additional conditions present at enrollment; concomitant autoimmune diseases, including Hashimoto\'s, were not uncommon (‎Table[1](#all13209-tbl-0001){ref-type="table-wrap"}).

###### 

Patient characteristics

  Patient characteristic                                     Total (N=673)
  ---------------------------------------------------------- ------------------
  Age at enrollment (y)                                      
  Mean (SD)                                                  48.8 (15.47)
  Median (range)                                             48.0 (19.0‐89.0)
  Age at symptom onset (y)                                   
  Mean (SD)                                                  42.3 (16.54)
  Median (range)                                             42.0 (7.0‐88.0)
  Age at diagnosis (y)                                       
  Mean (SD)                                                  44.2 (15.92)
  Median (range)                                             44.0 (10.0‐88.0)
  Disease duration from symptom onset to diagnosis (mo)      
  Mean (SD)                                                  24.0 (63.36)
  Median                                                     4.7
  Disease duration from diagnosis to study enrollment (mo)   
  Mean (SD)                                                  57.7 (77.79)
  Median                                                     27.7
  Sex                                                        
  Female                                                     489 (72.7%)
  Race and ethnicity (n=571)                                 
  Caucasian/white                                            516 (90.4%)
  Asian                                                      15 (2.6%)
  Hispanic                                                   10 (1.8%)
  Other                                                      20 (3.5%)
  Data not available                                         10 (1.8%)
  Concomitant diagnoses at enrollment                        
  Autoimmune diseases                                        
  Lupus                                                      2 (0.3%)
  Hashimoto\'s                                               45 (6.7%)
  Vitiligo                                                   3 (0.4%)
  Diabetes mellitus                                          12 (1.8%)
  Rheumatoid arthritis                                       4 (0.6%)
  Other autoimmune disease                                   35 (5.2%)
  Connective tissue disease(s)                               6 (0.9%)
  Myeloproliferative disease                                 1 (0.1%)
  Asthma                                                     76 (11.3%)
  Atopic eczema                                              21 (3.1%)
  Allergic rhinitis                                          111 (16.5%)
  History of allergic disease                                94 (14.0%)
  Family history of allergic disease                         95 (14.1%)
  Other                                                      68 (10.1%)
  Diagnostic testing to exclude trigger factors (n=671)      
  Yes                                                        504 (75.1%)
  No                                                         137 (20.4%)
  Data not available                                         30 (4.5%)

SD=standard deviation.

Other includes individuals of Black, Turkish, Arabic, and other ethnic backgrounds, as well as individuals of mixed ethnic background.

John Wiley & Sons, Ltd

3.2. Urticaria activity {#all13209-sec-0012}
-----------------------

The overall mean (SD) UAS7 score was 17.3 (10.49), suggesting moderate patient‐reported disease activity over 7 days despite treatment. Of the 605 people for whom a UAS7 score could be calculated, 299 (49.4%) had moderate‐to‐severe activity‎ despite treatment, with mean (SD) UAS7 scores of 21.5 (3.39) in the moderate and 33.3 (3.93) in the severe activity groups (Figure [2](#all13209-fig-0002){ref-type="fig"}).

![Urticaria Activity Score over 7 d (UAS7). SD=standard deviation; UAS7=Urticaria Activity Score over 7 d, twice‐daily assessment. Note: UAS7 scores were assessed by summing the average of twice‐daily assessments of hive count and itch score and summing these daily scores over 7 d](ALL-72-2005-g002){#all13209-fig-0002}

3.3. CSU has a major impact on HRQoL, sleep, and daily life {#all13209-sec-0013}
-----------------------------------------------------------

Mean (SD) total scores for the Chronic Urticaria Quality of Life Questionnaire (CU‐Q~2~oL) and Dermatology Life Quality Index (DLQI) were 33.6 (20.99) and 9.1 (6.62), respectively; 41.6% of patients had a mean DLQI score of 10 or above. The mean (SD) utility score estimate based on the generic EQ‐5D‐3L index was 0.714 (0.2907).

Overall, the most affected aspects of HRQoL were physical symptoms/discomfort, emotional well‐being, interference with daily activities, sleep, and work performance (Figure [3](#all13209-fig-0003){ref-type="fig"}). The most affected domains of the CU‐Q~2~oL[23](#all13209-bib-0023){ref-type="ref"} were pruritus (mean \[SD\] score, 55.2 \[27.88\]), sleep problems (38.3 \[25.69\]), and looks (35.5 \[25.34\]) (Figure [3](#all13209-fig-0003){ref-type="fig"}A). Among the six DLQI domains, negative impact was greatest on symptoms and feelings and daily activities (3.0 \[1.63\] and 1.9 \[1.72\], respectively, of a maximum possible domain score of 6) and work and school (1.6 \[0.97\] of a maximum possible domain score of 3) (Figure [3](#all13209-fig-0003){ref-type="fig"}B). The EQ‐5D‐3L domains for which patients most frequently reported moderate or extreme problems were pain/discomfort (63.2% of patients), anxiety/depression (47.4%), and usual activities (34.2%) (Figure [3](#all13209-fig-0003){ref-type="fig"}C).

![Impact of CSU on HRQoL, sleep, and daily life. (A). CU‐Q~2~oL total and domain scores, overall and by disease activity^a,b^. (B). DLQI domain scores, overall and by disease activity^c^. (C). Moderate and extreme problems on EQ‐5D‐3L domains, overall and by disease activity^c,d^. (D). Interference with sleep and interference with daily activities, overall and by disease activity^c,e^. CSU=chronic spontaneous urticaria; CU‐Q~2~oL=Chronic Urticaria Quality of Life Questionnaire; DLQI=Dermatology Life Quality Index; SD=standard deviation; UAS7=Urticaria Activity Score over 7 d, twice‐daily assessment. ^a^ CU‐Q~2~oL results exclude Germany, where the domains differ. Results for Germany can be found in Table [S4](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S4. ^b^Ns in legend represents the total number of survey completers in each UAS7 score band. Some of these patients had insufficient data to calculate an overall score and/or individual domain scores. ^c^Ns in legends represents the total number of survey completers in each UAS7 score band. Some of these patients had insufficient data to calculate domain scores. ^d^Patterned bars indicate the percentage of patients overall or in each score band with moderate problems, and solid bars indicate the percentage of patients overall in each score band with extreme problems. ^e^Weekly score is calculated as the sum of daily sleep or daily interference scores (range of 0 \[no interference\] to 3 \[substantial interference\]), divided by the number of nonmissing daily scores, multiplied by 7](ALL-72-2005-g003){#all13209-fig-0003}

Chronic spontaneous urticaria also had an impact on sleep and daily activities, as shown by weekly mean (SD) scores on the interference with sleep (6.6 \[5.93\]) and interference with daily activities (6.4 \[5.55\]) domains of the Urticaria Patient Daily Diary (UPDD) (Figure [3](#all13209-fig-0003){ref-type="fig"}D). The Work Productivity and Activity Impairment (WPAI) results substantiated these findings: One‐third of patients reported considerable impairments (mean \[SD\] 32.8% \[28.96%\]) in daily nonwork activities.

Across nearly all HRQoL domains, impact increased with increasing CSU activity.

3.4. CSU‐associated angioedema is a common and debilitating problem {#all13209-sec-0014}
-------------------------------------------------------------------

According to medical records, 58.5% (394 of 673) patients were reported to have had CSU‐associated angioedema, and 41.0% (276 of 673) had experienced CSU‐associated angioedema within the past 12 months from inclusion. According to the patient survey, 65.8% of patients (427 of 649) reported experiencing angioedema during the previous 12 months; of these, 75.2% (321 of 427) reported having experienced angioedema within the past 4 weeks. Patients with angioedema reported on a scale of 0‐10 the amount of itching (mean \[SD\] 7.2 \[2.16\]), swelling (7.3 \[2.73\]), and pain (5.4 \[3.39\]) they experienced during a typical episode over the past 12 months. When asked what they would typically do when they experienced angioedema, 21.5% of patients reported that they would go to the ED for treatment, 12.9% would take an over‐the‐counter medication, and 19.9% would do nothing. During the 7‐day UPDD period, 47.9% of patients (294 of 614) reported at least 1 day of angioedema. Occurrence of angioedema increased with disease activity, as more than two‐thirds of patients (70.1%) in the UAS7 28‐42 band reported experiencing angioedema on at least 1 of 7 consecutive days. The mean (SD) number of days with angioedema ranged from 2.3 (1.60) among patients in the UAS7 0‐6 band to 4.1 (2.18) days among patients in the UAS7 28‐42 band.

Angioedema significantly affected HRQoL, particularly emotional well‐being. Mean (SD) Angioedema Quality of Life Questionnaire (AE‐QoL) scores were 65.0 (25.14) on the fears/shame domain and 52.1 (25.83) on the fatigue/mood domain among all patients experiencing angioedema; patients with greater CSU activity reported more significant impacts on these domains (Figure [4](#all13209-fig-0004){ref-type="fig"}).

![AE‐QoL domain scores, overall and by disease activity. AE‐QoL=Angioedema Quality of Life Questionnaire; UAS7=Urticaria Activity Score over 7 d, twice‐daily assessment. Ns in legend represents the total number of patients in each UAS7 score band who reported angioedema over the past 4 wk in the patient survey. Some patients had insufficient data to calculate one or more AE‐QoL domain scores](ALL-72-2005-g004){#all13209-fig-0004}

3.5. CSU affects work performance and productivity {#all13209-sec-0015}
--------------------------------------------------

Of the 604 patients reporting, 341 (56.5%) indicated that they were currently employed. Among employed patients, the mean (SD) absenteeism, presenteeism, and overall work impairment were 6.1% (17.83%), 25.2% (25.78%), and 26.9% (27.53%), respectively, over the previous 7 days. Among the 329 employed patients responding, 72 (21.9%) had missed at least 1 hour of work in the past 7 days because of problems associated with CSU; among these, 45 patients (62.5%) missed up to 1 day of work and 27 (37.5%) missed more than 1 day in the past 7 days. The main reasons affecting capacity to work were itching (39.8%) and angioedema (28.2%).

Disease activity affected work performance, and greater disease activity had a greater negative productivity impact: mean (SD) overall work productivity loss was 11.9% (21.55%) among those with lowest disease activity and 43.6% (28.38%) among those with highest disease activity. Presenteeism (ie, impairment while at work) was the primary driver for overall work productivity loss, ranging from a mean (SD) of 9.8% (15.94%) among those with lowest disease activity to 40.4% (27.42%) among those with highest disease activity (Figure [S2](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S2).

3.6. Treatment of inadequately controlled CSU is frequently inconsistent with guideline recommendations {#all13209-sec-0016}
-------------------------------------------------------------------------------------------------------

In the preceding 12 months, 90.9% of patients received at least one‐second‐generation H~1~‐antihistamine (Figure [5](#all13209-fig-0005){ref-type="fig"}), and 45.2% of patients received updosing of H~1~‐antihistamines, or combinations of H~1~‐antihistamines plus leukotriene receptor antagonists (6.7%), or H~2~‐antihistamines (1.3%) or ciclosporin (1.2%), but remained symptomatic. Contrary to clinical guidelines,[34](#all13209-bib-0034){ref-type="ref"} 17.7% of patients received first‐generation H~1~‐antihistamines, and 19.3% of patients received oral corticosteroids for a mean (SD) duration of treatment of 153.2 (127.77) days (median, 118.0; range, 1.0‐366.0 days). Nearly one in five patients (18.1%) were not taking any therapy at enrollment.

![Therapies used in the past 12 mo (N=673). LTRA=leukotriene receptor antagonists. Other immunosuppressants included methotrexate and mycophenolate mofetil; other specified therapies included intravenous immunoglobulin, narrowband ultraviolet B procedure, dapsone, hydroxychloroquine, levamisole, mesalazine, sulfasalazine, nifedipine, stanozolol, and warfarin. Multiple H~1~‐antihistamines included combinations of second‐ and/or third‐generation H~1~‐antihistamine therapies, as well as patients who have multiple records of the same H~1~‐antihistamine](ALL-72-2005-g005){#all13209-fig-0005}

3.7. CSU has a considerable impact on healthcare resources {#all13209-sec-0017}
----------------------------------------------------------

Overall, 72.1% of patients had at least one visit to a healthcare professional for their CSU recorded in their medical record in the previous 12 months, with a mean (SD) of 3.3 (3.03) visits. According to medical records, consultant allergists (39.0%) and dermatologists (38.5%) were the most common specialists visited in the 12 months prior to enrollment. Among the 97 patients (14.4%) with at least one CSU‐related ED visit in the past 12 months, the annual mean (SD) number of visits was 1.8 (1.26). Hospitalization for CSU was recorded for 55 patients (8.2%), with a mean (SD) length of stay per hospitalization of 3.7 (2.67) days; 53.8% of hospital admissions were due to nonspecified diagnostic testing, 17.3% were due to angioedema, and the remaining admissions were for other unspecified reasons. Based on patients' survey responses, in the prior 3 months, patients most frequently visited a family doctor (44.8%) a mean (SD) of 2.7 (3.02) times (among patients with such a visit); 37.4% reported seeing a dermatologist a mean (SD) of 2.5 (2.55) times (among patients with such a visit).

3.8. CSU is costly for society {#all13209-sec-0018}
------------------------------

Total average (SD) annual direct costs per patient per year, as captured in the retrospective medical record review, ranged from PPP\$907.1 (\$2431.14) in Italy to PPP\$2984.2 (\$8969.46) in France. The major drivers of these costs were therapies (range, PPP\$426.4‐\$1788.7) and inpatient visits (range, PPP\$250.7‐\$1074.4) (Tables [S5](#all13209-sup-0001){ref-type="supplementary-material"} and [S6](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S5 and S6).

Average indirect costs, or costs of patient‐reported total work productivity loss over 4 weeks, were driven primarily by the cost of presenteeism (range, PPP\$544.5‐\$1180.0); the mean (SD) cost of work productivity loss ranged from PPP\$544.8 (\$603.22) in France to PPP\$1287.4 (\$1123.80) in Germany (Table [S7](#all13209-sup-0001){ref-type="supplementary-material"} in Appendix S7).

4. DISCUSSION {#all13209-sec-0019}
=============

To our knowledge, the ASSURE‐CSU study is the first international analysis of the burden of CSU inadequately controlled by standard treatment. We report novel findings for current treatment patterns, impact on HRQoL, and the economic burden to patients, healthcare systems, and society. A key strength is the use of a patient survey and retrospective medical record review to provide more comprehensive evidence than is captured using only administrative data sources (e.g., medical claims). As both disease activity and HRQoL were evaluated over a similar period, the impact of varying levels of disease activity on patients' lives was clarified. Moreover, we identified significant humanistic and economic burdens relating to CSU that have not been reported previously. Nevertheless, estimates of disease burden from this study may be conservative, and the observed treatment patterns might not represent the general CSU population. Patients were recruited from urticaria specialty centers and, as such, were receiving expert care for CSU.

Most patients in ASSURE‐CSU had moderate‐to‐severe physician‐assessed disease activity at diagnosis, and patients experienced a mean delay of 24 months (and a median delay of nearly 5 months) from symptom onset to diagnosis; mean duration from diagnosis to enrollment was nearly 5 years. Most patients continued to have moderate‐to‐severe disease activity (ie, moderate‐to‐severe itch and hives at least 4 days a week) while completing the patient diary. However, treatment could be suboptimal and in fact was absent for some patients during the study period. Patients not receiving treatment may have discontinued previous treatments owing to ineffectiveness or cost factors, among other reasons.

Angioedema was found to be more frequent than previously thought: Physicians reported that nearly 60% of patients with CSU experienced angioedema, and two‐thirds of them had experienced it within the past 12 months. More patients than physicians reported angioedema during this time period and reported its considerable impact on emotional well‐being, fatigue, and mood. Our findings suggest that angioedema plays a significant role in the burden of CSU, affecting every aspect of HRQoL and driving direct costs. Further analyses of ASSURE‐CSU data are ongoing to examine the misalignment between physicians' and patients' reports and to better understand the impact of angioedema.

Mean DLQI scores in this study suggest that CSU has a moderate impact on patients' HRQoL,[35](#all13209-bib-0035){ref-type="ref"} which is greater than previously thought; further, more than 40% had DLQI scores of 10 or greater, which, in psoriasis, justifies the initiation of a biologic.[36](#all13209-bib-0036){ref-type="ref"} In addition, HRQoL impairments correlated with disease activity, notably so in daily activity and sleep interference domains across measures. Particularly in patients with a UAS7 of 16 or greater, overall impact of CSU on usual activities represents a significant burden to themselves and to society.

Some notable differences were observed between patient and physician reporting, potentially suggesting that patients may not always communicate their urticaria symptoms to their physicians, in turn mitigating physicians' ability to treat effectively. Unanswered questions remain about patients' abilities to accurately identify or recall angioedema symptoms and physicians' likelihood of capturing these events in medical records. Discrepancies also existed between physicians' and patients' reports of resources used---specifically visits to other healthcare professionals and medications, particularly alternative therapies (eg, homeopathic treatments), that the patient was using. More research is needed to fully address these differences and provide education and resources to patients and providers alike.

ASSessment of the Economic and Humanistic Burden of Chronic Spontaneous/Idiopathic URticaria patiEnts provides valuable insight into the economic burden of CSU. To our knowledge, only a US claims database analysis,[37](#all13209-bib-0037){ref-type="ref"} a small US single‐center analysis,[38](#all13209-bib-0038){ref-type="ref"} and a cost‐effectiveness analysis in France[39](#all13209-bib-0039){ref-type="ref"} have previously evaluated CSU‐associated costs, and none is directly comparable with our study. Although previously thought to be infrequent, CSU‐related ED visits in ASSURE‐CSU were reported for 14% of patients, and hospitalizations were reported for 8% of patients. This is in contrast to Broder and colleagues'[37](#all13209-bib-0037){ref-type="ref"} findings in the United States that 2% of patients with CSU (of any severity) had CSU‐related ED visits and 0.1% of patients were hospitalized. Differences in national healthcare systems and in CSU severity among the study populations may contribute to the discrepancy in hospitalization patterns. However, Broder and colleagues found a similar number of annual office visits for CSU (3.4 vs 3.3 in ASSURE‐CSU). Moreover, in ASSURE‐CSU, CSU‐related out‐of‐pocket expenses to patients averaged nearly PPP\$500 per year and approached PPP\$1000 in Canada. As patients in our study were still symptomatic despite treatment, many sought alternative medical therapies, which are generally not covered by country health insurances. In addition, CSU considerably affected productivity, such that one in five patients took time off from work and one in four experienced reduced productivity at work. These findings are comparable with work productivity impairments in chronic urticaria[15](#all13209-bib-0015){ref-type="ref"}, [16](#all13209-bib-0016){ref-type="ref"}, [17](#all13209-bib-0017){ref-type="ref"} and in other dermatologic conditions, including atopic dermatitis,[40](#all13209-bib-0040){ref-type="ref"}, [41](#all13209-bib-0041){ref-type="ref"} plaque psoriasis,[42](#all13209-bib-0042){ref-type="ref"} and severe psoriasis.[16](#all13209-bib-0016){ref-type="ref"}, [43](#all13209-bib-0043){ref-type="ref"}, [44](#all13209-bib-0044){ref-type="ref"}

The reasons for ED visits and hospitalizations may center on patient and physician awareness and education. Depending on the healthcare system in a country, the use of this high‐cost care could be due to an inaccessibility of primary‐ or secondary‐care physicians for flare‐ups and steroid prescriptions. Alternatively, patients who have been treated in the ED before may feel that it is where CSU should be treated, or they may receive secondary gain from this visit, such as sick leave. In certain circumstances, hospitalization may be used for observation or to manage angioedema when anaphylaxis is feared by inexperienced ED physicians or because of delays in specialist referral.

Treatment modalities reported included therapies recommended in the current guidelines during the study period. However, patients were not always treated along formal guideline recommendations: For example, sedating first‐generation H~1~‐antihistamines, intravenous immunoglobulin, and long‐term oral corticosteroids were not uncommon. These results suggest that, at the time of study, some providers may have had insufficient resources or knowledge in treating patients with CSU. They may have resorted to trial‐and‐error approaches with therapies that carry significant side‐effect risks and lack efficacy evidence,[2](#all13209-bib-0002){ref-type="ref"} particularly when treating patients refractory to standard licensed therapy. Moreover, the monoclonal antibody omalizumab was included in the urticaria treatment guidelines in 2013[2](#all13209-bib-0002){ref-type="ref"} and was approved for inadequately controlled CSU in 2014. However, omalizumab had not yet launched in the study countries during data collection, and few patients (\<6%) in this study were treated with it. Future research should explore how disease burden and outcomes in CSU are affected by the introduction of omalizumab, its inclusion in the clinical guidelines, and its uptake in clinical practice.

While the study used a systematic patient selection method, a similar approach was not possible for physician and center selection due to the small number of specialist units for this population. Centers were selected to achieve variation in location, specialty, size, and type, but the resulting sample is not guaranteed to be representative of all centers and physicians treating patients with CSU. Likewise, inclusion criteria required patients to be symptomatic despite treatment and thus, the study does not reflect the entire population of patients with CSU.

Data and information about symptoms, HRQoL, and out‐of‐pocket expenses collected in the patient survey may have been subject to recall bias. The recall period for validated PROs varied from 7 days for the DLQI to 4 weeks for the AE‐QoL and for the patient medical resource survey was limited to 3 months to minimize the potential for such bias. While there was some heterogeneity across countries, results were strikingly similar particularly with respect to HRQoL.

Additional research is needed to explore patient characteristics, given that most patients in ASSURE‐CSU were Caucasian and (consistent with previous findings[45](#all13209-bib-0045){ref-type="ref"}, [46](#all13209-bib-0046){ref-type="ref"}) female, as well as patterns relating to disease activity and duration of disease. Because of the inherent fluctuations in CSU activity, longer or repeated assessments would help confirm the results. The impact of CSU on work performance and productivity warrants additional evaluation. Our findings suggest that there may be inadequate knowledge among medical staff of the appropriate workup for CSU, and there is a need to increase awareness of the economic and humanistic impact of CSU among primary‐ and secondary‐care providers and society in general.

5. CONCLUSIONS {#all13209-sec-0020}
==============

Chronic spontaneous urticaria is a chronic, disabling disease with little previous research that is challenging to treat adequately. The humanistic and economic burden of CSU has been underestimated. There is considerable delay in diagnosis and specialist referral, and there is inadequate knowledge among medical staff in primary and secondary care about CSU. Incorrect treatment patterns have been identified, and the high cost of unnecessary investigations and treatments is due to poor compliance with guidelines and best practices. Additional analyses should explore these findings in detail. To address unmet needs in CSU, it will be important to promote treatment guidelines and evidence‐based practices among healthcare providers.
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